Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
The company is also developing Entinostat.
It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 24 | -0.98 Decreased by -34.25% | -1.11 Increased by +11.71% |
| Aug 1, 24 | -0.80 Decreased by -25.00% | -0.91 Increased by +12.09% |
| May 8, 24 | -0.85 Decreased by -44.07% | -0.98 Increased by +13.27% |
| Feb 27, 24 | -1.00 Decreased by -61.29% | -0.99 Decreased by -1.01% |
| Nov 2, 23 | -0.73 Decreased by -25.86% | -0.80 Increased by +8.75% |
| Aug 3, 23 | -0.64 Decreased by -3.23% | -0.73 Increased by +12.33% |
| May 8, 23 | -0.59 Increased by +6.35% | -0.60 Increased by +1.67% |
| Feb 28, 23 | -0.62 Decreased by -134.25% | -0.65 Increased by +4.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 12.50 M Increased by +N/A% | -84.13 M Decreased by -64.48% | Decreased by -673.01% Decreased by N/A% |
| Jun 30, 24 | 3.50 M Increased by +N/A% | -68.06 M Decreased by -52.56% | Decreased by -1.94 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -72.40 M Decreased by -100.03% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 536.00 K Increased by +N/A% | -72.47 M Decreased by -99.60% | Decreased by -13.52 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -51.15 M Decreased by -43.41% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -44.62 M Decreased by -18.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -36.19 M Increased by +3.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -36.31 M Decreased by -137.74% | Decreased by N/A% Decreased by N/A% |